Danish drugmaker Novo Nordisk bets $145 million on post-Brexit UK science
Reuters: Health News
LONDON (Reuters) - Novo Nordisk, the world's top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research centre in Britain, undeterred by Brexit.
AMSTERDAM (Reuters) - The Netherlands has committed $10 million for an initiative to replace funding for abortion services in developing countries that will be lost due to U.S. President Donald Trump's ban on financing foreign groups that provide abortions.
LONDON (Reuters) - European prices for some off-patent cancer drugs have risen by more than 100 percent in the past five years, with two cases of hikes exceeding 1,000 percent, according to data presented at a medical conference on Saturday.
Fathers are conspicuously absent from studies that test the best ways to prevent and treat obesity in children, according to an analysis of research done in the past decade.
Elderly patients who get treated for illnesses or injuries in the emergency department (ED) are at risk of increased disability for up to six months afterward, a recent study suggests.
Complementary and alternative medicine options may help men manage premature ejaculation, according to a new review of existing research.
LONDON (Reuters) - British authorities say they have confirmed two more bird flu cases on farms in northern and eastern England, meaning there are now four areas where restrictions are in place across the country to reduce the spread of the disease.
WASHINGTON (Reuters) - U.S. Vice President Mike Pence fired up tens of thousands of anti-abortion activists who gathered on Friday for the 44th March for Life, celebrating a political shift in their favor with the election of President Donald Trump.
LITTLE ROCK, Ark. (Reuters) - Arkansas Governor Asa Hutchinson signed into law on Thursday a bill banning the most common abortion procedure employed in the second trimester of a pregnancy, among the most restrictive abortion legislation in the United States.
ZURICH (Reuters) - Roche's cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker's treatment is making up lost ground.
No comments:
Post a Comment